Oncology

Neurotoxicity (e.g., seizures, cerebral edema)

Carmustine

Hemorrhagic Cystitis

Cyclophosphamide

Ifosfamide

Diarrhea

Irinotecan

Peripheral Neuropathy

Platinum-based Compunds (e.g., cisplatin, oxaliplatin)

Vinca alkaloids (e.g., vinblastine, vincristine)

Taxanes (e.g., docetaxel, paclitaxel)

Bone Marrow Suppression

Most chemotherapy EXCEPT bleomycin, pegaspargase, and vincristine

Ototoxicity

Cisplatin

High Emetogenicity

Cisplatin

Nephrotoxicity

Cisplatin

Methotrexate

Mucositis

Methotrexate

Fluorouracil

Capecitabine

Pulmonary Toxicity (e.g., Pulmonary Fibrosis)

Bleomycin

Busulfan

Carmustine

Cardiotoxicity (e.g., Cardiomyopathy)

Anthracyclines (e.g., Doxorubicin)

Hand-Foot Syndrome

Capecitabine

Fluorouracil

Prevention of Nephrotoxicity

Amifostine

Limit cisplatin dose to less than 100 mg/m²

Prevention of Hemorrhagic Cystitis

Mesna

Prevention of Diarrhea

Atropine

Prevention of Peripheral Neuropathy

Oxaliplatin: Avoid cold exposure

Vincristine: Limit single doses to 2 mg

Prevention of Mucositis

High-dose Methotrexate: Leucovorin

Prevention of Pulmonary Toxicity

Bleomycin: Limit lifetime cumulative dose to 400 units

Prevention of Cardiotoxicity

Dexrazoxane

Limit lifetime cumulative dose to 450-550 mg/m²

Treatment of Hand-Foot Syndrome

Uridine Triacetate

Rituximab Target

CD20

Rituximab Safety Concern

Hepatitis B Reactivation

Cetuximab Target

EGFR Gene Expression

Cetuximab Safety Concern

Acneiform Rash

Trastuzumab Target

HER2 Overexpression

Trastuzumab Safety Concern

Cardiotoxicity (e.g., Cardiomyopathy)

Bevacizumab Target

None

VEGF Inhibitor

Bevacizumab Safety Concern

Impaired Wound Healing

Thromboembolic Events

Fatal Bleeding

GI Perforation

Pembrolizumab Target

PD-1 Receptor

Nivolumab Target

PD-1 Receptor

Pembrolizumab Safety Concern

Immune-Mediated Toxicities (e.g., Endocrinopathies, Colitis, Hepatotoxicity, Pneumonitis, Thyroid Disorders)

Nivolumab Safety Concern

Immune-Mediated Toxicities (e.g., Endocrinopathies, Colitis, Hepatotoxicity, Pneumonitis, Thyroid Disorders)

Ipilimumab Target

CTLA-4

Ipilimumab Safety Concern

Immune-Mediated Toxicities (e.g., Endocrinopathies, Colitis, Hepatotoxicity, Pneumonitis, Thyroid Disorders)

Imatinib Target

BCR-ABL Fusion Gene

Imatinib Safety Concern

Fluid Retention

QT Prolongation

GI Upset

Dabrafenib Target

BRAF V600E or V600K Mutation

Dabrafenib Safety Concern

New Malignancies

QT Prolongation

Vemurafenib Target

BRAF V600E or V600K Mutation

Vemurafenib Safety Concern

New Malignancies

QT Prolongation

Cobimetinib Target

BRAF V600E or V600K Mutation (In Combination With BRAF Inhibitor)

MEK Inhibitor

Cobimetinib Safety Concern

Retinopathy

Rhabdomyolysis

Trametinib Target

BRAF V600E or V600K (In Combination With BRAF Inhibitor)

MEK Inhibitor

Trametinib Safety Concern

Retinopathy

Rhabdomyolysis

Afatinib Target

EGFR Gene Mutation

Afatinib Safety Concern

Acneiform Rash

Erlotinib Target

EGFR Gene Mutation

Erlotinib Safety Concern

Acneiform Rash